NCCN Awarded $2 Million in Research Funding From Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers
The NCCN Oncology Research Program (ORP) Was Awarded a $2-Million Grant From Peregrine Pharmaceuticals, Inc. to Facilitate Studies of Bavituximab in Various Cancers
